KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Thermo Fisher Scientific (TMO) over the last 16 years, with Sep 2025 value amounting to $103.0 billion.

  • Thermo Fisher Scientific's Liabilities and Shareholders Equity rose 2.65% to $103.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $400.6 billion, marking a year-over-year increase of 1.50%. This contributed to the annual value of $97.3 billion for FY2024, which is 1.42% down from last year.
  • Thermo Fisher Scientific's Liabilities and Shareholders Equity amounted to $103.0 billion in Q3 2025, which was up 1.77% from $101.2 billion recorded in Q2 2025.
  • Thermo Fisher Scientific's 5-year Liabilities and Shareholders Equity high stood at $103.0 billion for Q3 2025, and its period low was $65.9 billion during Q2 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $98.3 billion, with a median of $98.5 billion in 2024.
  • In the last 5 years, Thermo Fisher Scientific's Liabilities and Shareholders Equity spiked by 40.67% in 2022 and then declined by 1.42% in 2024.
  • Thermo Fisher Scientific's Liabilities and Shareholders Equity (Quarterly) stood at $95.1 billion in 2021, then grew by 2.14% to $97.2 billion in 2022, then climbed by 1.62% to $98.7 billion in 2023, then declined by 1.42% to $97.3 billion in 2024, then climbed by 2.65% to $103.0 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $103.0 billion for Q3 2025, versus $101.2 billion for Q2 2025 and $99.0 billion for Q1 2025.